Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

  • Martina Vispi | martinavispi@yahoo.it Dermatology Unit, Misericordia Hospital, Grosseto, Italy.
  • Teresa Corradin Dermatology Unit, Pordenone Hospital, Pordenone, Italy.
  • Camilla Peccianti Dermatology Unit, Misericordia Hospital, Grosseto, Italy.
  • Luca Feci Dermatology Unit, Misericordia Hospital, Grosseto, Italy.
  • Laura Casini Dermatology Unit, Misericordia Hospital, Grosseto, Italy.
  • Chiara Pisani Dermatology Unit, Misericordia Hospital, Grosseto, Italy.
  • Susanna Fabbroni Dermatology Unit, Misericordia Hospital, Grosseto, Italy.
  • Paola Corsetti Dermatology Unit, Pordenone Hospital, Pordenone, Italy.
  • Margherita Croatto Dermatology Unit, Pordenone Hospital, Pordenone, Italy.
  • Michele Pellegrino Dermatology Unit, Misericordia Hospital, Grosseto, Italy.

Abstract

On January 30, 2020, World Health Organization (WHO) stated that a new coronavirus disease outbreak [COronaVIrus Disease - 19 (COVID-19)] was an international public health emergency. Many news, often fake ones, about the derived pandemic rapidly spread along the media, thus leading many dermatological patients to identify as “risk category” and sometimes discontinue treatments by themselves. The Dermatology Units in Grosseto and Pordenone simultaneously carried out a data collection by remote-conducted visits, evaluating the incidence of COVID-19 in psoriatic patients. Only 1 patient (close contact of a case) as part of the psoriasis analyzed group was tested and turned out to be positive for SARS-CoV-2, developing no symptoms during the observation period. The collected information may suggest that psoriasis, biotechnologically treated or not, cannot promote or aggravate the clinical trend of the SARS-CoV-2 infection, hence stopping systemic therapy in negative or clinically free SARS-CoV-2 patients is not recommended in general.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

Qun Li, Xuhua Guan, Peng Wu et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. New Engl J Med 2020 Mar 26;382(13):1199-1207.
Public Health Emergency of International Concern (PHEIC) - (World Health Organization (WHO). Statement on the second meeting of the International Health Regulations (2 0 0 5). Emergency Committee regarding the outbreak of novel coronavirus (201 9 - nCoV).
Lambert TW, Soskolne CL, Bergum V et al. Ethical perspectives for public and environmental health:fostering autonomy and the right to know. Environ Health Perspect 2003 Feb; 111(2): 133–137.
Published
2020-06-25
Info
Issue
Section
Brief Reports
Keywords:
COVID-19, Psoriasis, Biological Drugs
Statistics
  • Abstract views: 188

  • PDF: 141
  • HTML: 0
How to Cite
Vispi, M., Corradin, T., Peccianti, C., Feci, L., Casini, L., Pisani, C., Fabbroni, S., Corsetti, P., Croatto, M., & Pellegrino, M. (2020). Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces. Dermatology Reports, 12(1). https://doi.org/10.4081/dr.2020.8642